Vanguard Group Inc. lessened its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,848,923 shares of the company's stock after selling 38,287 shares during the quarter. Vanguard Group Inc. owned 5.80% of Day One Biopharmaceuticals worth $74,106,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of DAWN. R Squared Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth $31,000. E Fund Management Co. Ltd. purchased a new stake in Day One Biopharmaceuticals in the 4th quarter worth $143,000. KLP Kapitalforvaltning AS acquired a new position in Day One Biopharmaceuticals during the fourth quarter worth $150,000. XTX Topco Ltd purchased a new position in Day One Biopharmaceuticals in the 3rd quarter valued at about $178,000. Finally, Teacher Retirement System of Texas increased its position in shares of Day One Biopharmaceuticals by 20.9% during the fourth quarter. Teacher Retirement System of Texas now owns 17,825 shares of the company's stock worth $226,000 after purchasing an additional 3,086 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages have recently weighed in on DAWN. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group decreased their price target on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. Wedbush reissued an "outperform" rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. Bank of America reduced their price objective on Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of "Buy" and a consensus target price of $32.29.
Check Out Our Latest Stock Report on Day One Biopharmaceuticals
Insider Buying and Selling
In related news, CEO Jeremy Bender sold 12,048 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now owns 128,015 shares of the company's stock, valued at approximately $1,531,059.40. The trade was a 8.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares of the company's stock, valued at approximately $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,064 shares of company stock worth $251,925 in the last ninety days. Insiders own 8.40% of the company's stock.
Day One Biopharmaceuticals Stock Performance
DAWN traded down $0.22 during trading on Wednesday, hitting $6.97. The stock had a trading volume of 71,523 shares, compared to its average volume of 1,116,006. The firm has a market capitalization of $706.44 million, a P/E ratio of -6.78 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a twelve month low of $6.41 and a twelve month high of $18.07. The company's 50-day moving average price is $9.13 and its 200 day moving average price is $11.95.
Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million. As a group, equities analysts expect that Day One Biopharmaceuticals, Inc. will post -0.72 earnings per share for the current fiscal year.
About Day One Biopharmaceuticals
(
Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Further Reading
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
